Catalent, Inc. (CTLT): Matthew M Walsh , officer of Catalent, Inc. sold 21,197 shares on May 27, 2016. The Insider selling transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were sold at $28.85 per share for a total value of $611,533.44 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 19, 2015, John R Chiminski (director officer ) sold 38,505 shares at $33.87 per share price.On Jul 29, 2015, Matthew M Walsh (officer ) sold 27,172 shares at $31.18 per share price.Also, On Apr 3, 2015, Scott Houlton (officer ) sold 16,253 shares at $30.61 per share price.On Apr 3, 2015, Aristippos Gennadios (officer ) sold 24,868 shares at $30.61 per share price.
Shares of Catalent Inc (CTLT) ended Wednesday, Jun 1, 2016 session in red amid volatile trading. The shares closed down -0.31 points or -1.10% at $27.81 with 27,18,425 shares getting traded. Post opening the session at $28.14, the shares hit an intraday low of $27.49 and an intraday high of $28.62 and the price vacillated in this range throughout the day. The company has a market cap of $3,467 M and the number of outstanding shares has been calculated to be 12,46,59,595 shares. The 52-week high of Catalent Inc is $34.415 and the 52-week low is $18.92.
Company has been under the radar of several Street Analysts.Catalent Inc is Downgraded by BofA/Merrill to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 5, 2016.Catalent Inc is Downgraded by Morgan Stanley to Equal-Weight. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Apr 21, 2016.
Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.